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Abstract
Hereditary angioedema (HAE) is predominantly caused by a deficiency in C1 esterase inhibitor (C1INH) (HAE-
C1INH). C1INH inhibits activated factor XII (FXIIa), activated factor XI (FXIa), and kallikrein. In HAE-C1INH patients
the thrombotic risk is not increased even though activation of the contact system is poorly regulated. Therefore, we
hypothesized that contact activation preferentially leads to kallikrein formation and less to activation of the
coagulation cascade in HAE-C1INH patients. We measured the levels of C1INH in complex with activated contact
factors in plasma samples of HAE-C1INH patients (N=30, 17 during remission and 13 during acute attack) and
healthy controls (N=10). We did not detect differences in enzyme-inhibitor complexes between samples of controls,
patients during remission and patients during an acute attack. Reconstitution with C1INH did not change this result.
Next, we determined the potential to form enzyme-inhibitory complexes after complete in vitro activation of the
plasma samples with a FXII trigger. In all samples, enzyme-C1INH levels increased after activation even in patients
during an acute attack. However, the levels of FXIIa-C1INH, FXIa-C1INH and kallikrein-C1INH were at least 52%
lower in samples taken during remission and 70% lower in samples taken during attack compared to samples from
controls (p<0.05). Addition of C1INH after activation led to an increase in levels of FXIIa-C1INH and FXIa-C1INH
(p<0.05), which were still lower than in controls (p<0.05), while the levels of kallikrein-C1INH did not change. These
results are consistent with constitutive activation and attenuated depletion of the contact system and show that the
ongoing activation of the contact system, which is present in HAE-C1INH patients both during remission and during
acute attacks, is not associated with preferential generation of kallikrein over FXIa.
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Introduction
Hereditary angioedema (HAE) is a rare disorder
predominantly caused by reduced levels or activity of C1
esterase inhibitor (C1INH) due to a mutation in the genes
coding for C1INH (SERPING1). Patients with HAE experience
episodic swellings that affect the subcutaneous and
submucous tissues at the site of postcapillary venoles. Most
common are asymmetrical cutaneous swelling of the hands,
feet, face or genitals and swelling of the gastrointestinal tract.
Swelling of the respiratory tract is less frequent, but potentially
life-threatening [1]. Acute attacks of angioedema can be
treated 1) by replacing C1INH with the plasma purified or
recombinant protein; 2) by the plasma kallikrein inhibitor
ecallantide or 3) by the specific antagonist of the bradykinin B2
receptor icatibant [1].
There are three types of HAE described: type I and type II
are caused by either low levels of C1INH (type I) or
dysfunctional C1INH (type II) (HAE-C1INH) [1]. Subjects with
HAE type III have normal levels and activity of C1INH. In most
of these patients the genetic cause of HAE is unknown (HAE-
unknown). In one third, a point mutation (Thr328Lys or
Thr328Arg) or a deletion (deletion of 72 base pairs: c.
971_1018+24del72*) in the coagulation factor XII (FXII) gene is
found (HAE-FXII) [2,3]. HAE-C1INH is predominantly and all
HAE-FXII are inherited in an autosomal dominant fashion.
C1INH is a serine protease inhibitor and the main regulator
of the classical complement pathway (named to complement
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C1) and the contact activation system [4]. The contact system,
also known as the plasma kallikrein kinin system (PKKS),
consists of FXII, prekallikrein and high molecular weight
kininogen (HK). Activation of the contact system can initiate
coagulation via activation of factor XI (FXI). C1INH is able to
rapidly inhibit activated FXII (FXIIa), activated FXI (FXIa) and
kallikrein [5,6]. It is the main endogenous inhibitor of FXIIa,
kallikrein and FXIa: more than 90% of FXIIa, 50% of kallikrein
and 50% of FXIa are inhibited by C1INH in plasma of healthy
persons in in vitro experiments [6–8]. Other inhibitors of the
contact system and FXIa are: α1-antitrypsin (AT) and α2-
antiplasmin, which both inhibit FXIa for ~20-25% in vitro [8],
and α2-macroglobulin (α2M). Approximately 35% of kallikrein is
inhibited by α2M in vitro, however inhibition by C1INH is faster
than inhibition by α2M [6,9].
The contact activation system is triggered in vitro when FXII
is activated upon binding to negatively charged surfaces, such
as dextran sulphate (DXS) or kaolin. Several physiological
triggers of FXII have been identified, such as extracellular RNA
and long-chain polyphosphates released from bacteria,
however their contribution to activation in vivo is not yet clear
[10,11]. Binding of the proteins of the contact system to
endothelial cells initiates FXII-dependent conversion of
prekallikrein into kallikrein [12]. FXIIa is able to activate both
FXI and prekallikrein, HK is a nonenzymatic cofactor in these
activations. Activation of FXI starts the intrinsic pathway of
coagulation and results in the formation of thrombin and of a
fibrin clot. Cleavage of prekallikrein by FXIIa generates
kallikrein, which leads to the generation of bradykinin, via the
cleavage of HK by kallikrein. Liberated bradykinin is the main
mediator of symptoms in patients with HAE. Binding of
bradykinin to the bradykinin B2 receptor on endothelial cells
activates several intracellular signaling pathways that lead to
vasodilatation, increased vascular permeability and fluid efflux
[13,14].
During the attack phase of angioedema, activation of the
contact system is observed: the levels of cleaved HK and FXIIa
are elevated. The levels of prothrombin fragment 1.2 (a marker
of thrombin generation) and D-dimer (a marker of fibrin
degradation) are increased as well [15,16]. However,
thrombotic complications during attacks or increased
thrombotic risk in HAE-C1INH patients are not reported. It has
been shown that activation of FXII by misfolded protein
aggregates in patients with systemic amyloidosis leads to a
form of FXIIa which activates prekallikrein but not FXI [17].
Hence, in vivo, activation of the kallikrein system without
activation of the coagulation system can occur. This led to the
hypothesis that in patients with HAE-C1INH, activation of FXII
preferentially triggers prekallikrein activation, rather than FXIa
generation by FXIIa.
To test our hypothesis, we measured activation of the
contact system as 1) the levels of C1INH complexed with the
activated contact factors in plasma samples, and 2) the in vitro
potential of the plasma to form enzyme-inhibitory complexes
when the contact system is completely activated. We used two
different triggers of FXII, with different activation patterns, in
separate samples. These measurements were performed in
plasma obtained from HAE-C1INH patients during an attack
and during remission and were compared with measurements
in plasma from healthy controls.
Materials and Methods
Patients
In total, we analyzed 30 samples from patients with HAE-
C1INH and 10 samples from healthy controls. These samples
were obtained from 17 patients with HAE type I and 1 patient
with HAE type II, and from 10 healthy volunteers. We examined
13 samples taken during an attack (obtained from 8 different
patients) and 17 samples taken during remission from patients
with HAE-C1INH. From 7 patients we analyzed both samples
during attack and during remission.
Blood samples were collected in 3.2% sodium citrate as
anticoagulant. Before blood drawing, the tourniquet was
removed. The first 3 ml of blood was discarded. A subset of
samples was also collected in an antiprotease mix to prevent
activation of the contact system in vitro. The inhibitor cocktail
was prepared by dissolving benzamidine (100 mM),
hexadimethrine bromide (400 µg/ml), soybean trypsin inhibitor
(STI) (2 mg/ml), leupeptin (263 µM) and
aminoethylbenzenesulfonylfluoride (20 mM) in acid-citrate-
dextrose (100 mM trisodium citrate, 67 mM citric acid, and 2%
dextrose, pH 4.5). Blood was collected in a blood:
anticoagulant/inhibitor cocktail ratio of 9:1 [18]. The samples
were centrifuged at 2000g for 20 min at room temperature.
Aliquots of the plasma samples were immediately snap-frozen
in liquid nitrogen and stored at -80oC until use. Blood was
collected in the course of routine diagnostic procedures and all
patients gave oral informed consent that remaining plasma
could be used for research purposes. If consent was given by
the patient, the remaining plasma sample was labeled with a
code which was documented into a data sheet. The Ethical
Committee of the University of Milan approved of this study,
also indicating that written informed consent is not necessary if
the plasma is obtained during routine diagnostics and that this
plasma can be used for research investigating the
pathophysiology of hereditary angioedema.
Materials
Dextran sulfate (DXS; Mr 500 000), ellagic acid, Hepes, STI
and polybrene were from Sigma Chemical Co. (St Louis, Mo).
The 96-well plates used were Nunc maxisorb (Denmark).
Cetor® was from Sanquin (Amsterdam, the Netherlands). The
monoclonal antibodies were in house [19]. Normal platelet poor
pooled plasma (University Hospital, Maastricht) consisted of
plasma from 80 healthy volunteers.
The chromogenic assay for the measurement of C1INH
activity was from Technoclone GmbH (Wien, Austria). Radial
immunodiffusion assays for the detection of C1INH, C1q, and
C4 antigen levels were from Siemens Healthcare Diagnostics
(Munich, Germany). The chromogenic peptide kallikrein
substrate S-2302 was from Chromogenix, Instrumentation
Laboratory (Bedford, USA). For the measurement of cleaved
HK the goat polyclonal anti-HK light chain antibody was from
Nordic (Tilburg, the Netherlands) and the biotinylated rabbit
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anti-goat antibody and kallikrein from human plasma were from
Sigma Aldrich Co. (St Louis, USA).
Handling of the plasma
Inhibitory complexes were determined both directly in the
plasma samples (basal samples) and in the plasma samples
upon activation in vitro (activated samples). Furthermore, we
reconstituted C1INH (cetor®) in the plasma samples.
To basal plasma samples we added either Hepes-buffer (25
mM Hepes, 150 mM NaCl, pH = 7.5) or C1INH, to inhibit free
FXIa, FXIIa and kallikrein if present. The plasma samples were
placed for 10 minutes at 37oC to allow optimal C1INH complex
formation before stop buffer (containing STI and polybrene)
was added. For activation of plasma samples we used either
ellagic acid or DXS (Mr 500 000) for 15 min at 37oC. After
activation of the plasma, we added C1INH or Hepes-buffer. To
stop the reaction, we added stop buffer. Final concentrations of
the above reagents were: 20% plasma, 0.2 U/ml C1INH, 0.1
mg/ml ellagic acid, 0.1 mg/ml DXS, 0.03% polybrene and 0.06
mg/ml STI. These samples were further diluted in the assay.
Incubation of the plasma with ellagic acid or DXS leads to the
activation of FXII. FXII activation with ellagic acid leads to
activation of prekallikrein and FXI, whereas FXII activation with
DXS only leads to activation of prekallikrein and not of FXI.
Laboratory measurements
The assays for the detection of amidolytic activity of kallikrein
in plasma and capacity of plasma to inhibit kallikrein amidolytic
activity are based on a method described by Gallimore et al
[20] using the chromogenic substrate S-2302. The presence of
kallikrein amidolytic activity was measured by diluting the
plasma 1:20 in 0.05 M Tris, 0.11 M NaCl (pH = 7.8), incubating
it with the chromogenic substrate for 30 minutes at 37oC and
the rate of release of paranitroaniline (pNA) was measured
photometrically at 405 nm. To determine the capacity of
plasma to inhibit the amidolytic activity of exogenous kallikrein,
a fixed amount (0.06 U/ml) of purified human plasma kallikrein
was added to serial dilution of plasma. The release of pNA was
recorded after 5 minutes incubation at 37oC with the substrate.
The capacity of plasma to inhibit amidolytic activity of kallikrein
was expressed as percentage of normal using a standard
curve of normal human pooled plasma.
Cleaved HK was evaluated with sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS PAGE) and
immunoblotting analysis, as described previously [21].
Enzyme-linked immunosorbent assay (ELISA)
The levels of C1INH in complex with FXIIa, kallikrein and
FXIa (FXIIa-C1INH, KAL-C1INH, FXIa-C1INH) and AT in
complex with FXIa (FXIa-AT) were determined by ELISA as
described previously [19]. In short, the monoclonal antibody
(mAB) KOK-12 was used as a capture antibody for C1INH
complexed with FXIIa or kallikrein. FXIIa-C1INH was
recognized with the mAB F3 and KAL-C1INH with the mAB
K15. The mAB XI-5 was used as a capture mAB for FXI(a), the
mAB R11 recognized FXIa-C1INH and the mAB AT-15
recognized FXIa-AT. Absorbance was read at 450 nm on an
EL 808 Ultra microplate reader (Bio-tek Instruments Inc.,
Winooski, Vt).
Results are expressed in arbitrary units (A.U.) relative to a
standard curve obtained from normal pooled plasma maximally
activated with DXS (for FXIIa-C1INH and KAL-C1INH), or
activated with ellagic acid (for all four complexes: FXIIa-C1INH
and KAL-C1INH, FXIa-C1INH and FXIa-AT).
Statistical analysis
The data are expressed as median [interquartile range
(IQR)]. Differences between three or more groups were
determined using the Kruskal-Wallis test with Dunn’s post hoc
test. To determine if addition of C1INH to samples had an
effect on the enzyme-inhibitory complex levels, the Wilcoxon
Signed Rank Test was used. Correlations are expressed as
Spearman’s coefficient. Results were viewed to be statistically
significant different when p < 0.05. Statistical analyses were
performed using IBM SPSS Statistics 20 for Windows (Armonk,
New York: IBM Corp.) and Prism for Windows 5.00 (GraphPad
Software Inc., San Diego, CA, USA).
Results
The activity of C1INH, which is the main inhibitor of FXII
activation and FXIIa, is low in plasma samples of HAE-C1INH
patients, representing a risk for contact activation during blood
drawing and storage. Therefore, we determined if the storage
and preservation of plasma samples from patients with HAE-
C1INH led to activation of the contact system. We compared
samples taken at the same time in citrate alone and in an
inhibitor cocktail mixture which efficiently prevents in vitro
activation of the contact system [18]. We measured the levels
of FXIIa-C1INH, kallikrein-C1INH and FXIa-C1INH in plasma
samples obtained from 10 patients and from 10 healthy
individuals. Comparison of these levels showed no difference
between the two anticoagulants, both for the healthy individuals
and for the HAE-C1INH patients (see Table 1). Therefore, low
levels of C1INH in citrated plasma alone did not lead to contact
activation after blood drawing and we were able to use plasma
samples obtained from citrated blood for our study.
Study population
Table 2 summarizes the main laboratory indices of the study
population. The sex distribution is comparable between the
groups, however the healthy controls are younger than the
patients with HAE-C1INH. The C1INH antigen and activity
levels were reduced in patients and consequently, cleaved HK
and the spontaneous kallikrein activity were increased and the
capacity to the plasma to inhibit kallikrein decreased compared
to healthy controls.
We did not observe differences in the levels of the enzyme-
inhibitory complexes between healthy controls and patients,
both in samples taken during remission and in samples taken
during an acute attack of angioedema (see Table 2).
Furthermore, we substituted C1INH in these plasma samples,
and allowed free FXIa, FXIIa and kallikrein in these samples to
form complexes with C1INH. This had no effect on the complex
levels determined (data not shown).
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Activation of samples from patients
Since we did not observe a difference between the levels of
the activated contact factors in complex with their inhibitors in
the basal samples, we wanted to determine the potential to
form enzyme-inhibitory complexes after complete activation of
FXII. We used two different activators of FXII, namely ellagic
acid and DXS. Ellagic acid is a potent activator of FXII and is
commonly used as a reagent in the activated Partial
Thromboplastin Time (aPTT) test. DXS is mainly used in
research as a FXII activator [22]. As shown in Figure 1, in
normal pool plasma activation of FXII with ellagic acid activates
Table 1. Comparison of the levels of enzyme-inhibitory
complexes in samples taken in citrate and in inhibitor
cocktail as anticoagulant.
  
FXIIa-C1INH
(A.U.)
Kallikrein-C1INH
(A.U.)
FXIa-C1INH
(A.U.)
  Median [IQR] Median [IQR] Median [IQR]
HAE-
C1INH
patients
Citrate 0.73 [0.62-0.79] 0.5 [0.5 - 0.5] 1.37 [1.24-1.42]
 Inhibitorcocktail 0.75 [0.67-0.79] 0.5 [0.5 - 0.5] 1.28 [1.17-1.44]
Healthy
controls Citrate 0.62 [0.5-0.66] 0.5 [0.5 - 0.5] 1.31 [1.20-1.47]
 Inhibitorcocktail 0.64 [0.58-0.68] 0.5 [0.5 - 0.5] 1.26 [1.14-1.34]
C1INH: C1 esterase inhibitor; HAE: hereditary angioedema, IQR: interquartile
range; A.U: arbitrary units
Table 2. General characteristics of the study population.
 Healthy controls
HAE-C1INH
(remission)
HAE-C1INH
(acute attack)
 Median [IQR] Median [IQR] Median [IQR]
N 10 17 13
Gender (female) 9 13 10
Age (years) 21 [20-21] 48 [45-70] 48 [47-63]
C1INH function (%) 75.5 [69.8-82.5] 11.0 [0.0-18.5] 0.0 [0.0-5.75]
C1INH antigen (%) 100 [90-109] 25.0 [25.0 - 25.0] 9.0 [0.0-25.0]
Cleaved HK (%) 33.2 [30.4-38.0] 47.7 [42.2-48.1] 61.8 [56.5-70.3]
Capacity of the
plasma to inhibit
kallikrein (%)
120.8
[111.8-126.5] 56.0 [18.6-57.5] 25.5 [1.31-34.5]
Spontaneous
kallikrein activity
(mU/ml)
0.73 [0.44-1.89] 6.08 [2.15-13.0] 4.34 [2.09-16.21]
FXIIa-C1INH (A.U.) 0.62 [0.5-0.65] 0.72 [0.62-0.83] 0.67 [0.51-0.78]
Kallikrein-C1INH
(A.U.) 0.5 [0.5-0.51] 0.5 [0.5 - 0.5] 0.5 [0.5-1.30]
FXIa-C1INH (A.U.) 1.31 [1.20-1.47] 1.40 [1.29-1.47] 1.33 [1.27-1.44]
FXIa-AT (A.U.) 0.66 [0.5-0.74] 0.83 [0.68-0.87] 0.84 [0.75-0.97]
C1INH: C1 esterase inhibitor; HAE: hereditary angioedema, IQR: interquartile
range; HK: high molecular weight kininogen; A.U: arbitrary units
both prekallikrein and FXI, whereas FXII activated with DXS
only activates prekallikrein and not FXI. Since patients with
HAE-C1INH have low levels of functional C1INH we measured
the enzyme-inhibitor complexes directly after activation and
after addition of C1INH (1 U/ml plasma) to the activated plasma
in order to inhibit remaining, free FXIIa, kallikrein and FXIa.
Activation with ellagic acid.  Figure 2 and Table 3 show
the levels of the inhibitory complexes in patients with HAE-
C1INH and in healthy controls after activation with ellagic acid.
The levels of enzyme-C1INH complexes were higher in plasma
samples from healthy individuals than in the plasma samples of
patients, both in those taken during remission and those taken
during an acute attack. The levels of FXIIa-C1INH and FXIa-
C1INH increased significantly after addition of C1INH,
indicating that not all FXIIa and FXIa were inhibited after
activation with ellagic acid if no additional C1INH was added.
However, the levels of the inhibitory complexes remained lower
than those in healthy controls. The levels of kallikrein-C1INH
did not increase if C1INH was added after activation. In
comparison with healthy controls, the levels of FXIa-AT after
activation with EA were higher in patients during remission and
as expected these levels did not change after addition of
C1INH.
Since C1INH is an important inhibitor of kallikrein in vivo, we
examined if the capacity of the plasma to inhibit kallikrein and
the spontaneous kallikrein activity of the plasma correlate with
the levels of kallikrein-C1INH complexes. In activated plasma
samples, we observed a positive correlation between the levels
of kallikrein-C1INH and the capacity of the plasma to inhibit
kallikrein (r = 0.85, p < 0.001), and a negative correlation with
the spontaneous kallikrein activity (r = -0.66, p = 0.001).
Activation with dextran sulphate.  Next, we activated the
plasma samples with DXS (see Figure 3 and Table 4). As
expected, activation of plasma with DXS led to low levels of
FXIa-C1INH and FXIa-AT compared to activation with ellagic
acid. The levels of FXIa-C1INH were comparable between
healthy controls and HAE-C1INH patients. The levels of FXIa-
AT were higher in HAE-C1INH patients compared to healthy
controls, however for both groups the median levels were low
(less than 4 A.U. compared to approximately 100 A.U. after
activation with ellagic acid). The results for kallikrein-C1INH
after activation with DXS were largely comparable to those
after activation with ellagic acid. The levels of kallikrein-C1INH
were highest in healthy controls, there was no difference in
these levels between remission and attack samples. The level
of kallikrein-C1INH complexes did not increase after addition of
C1INH after activation of the plasma. The levels of FXIIa-
C1INH were highest in healthy controls and this was significant
if no C1INH was added after activation. Addition of C1INH led
to higher levels of FXIIa-C1INH in HAE-C1INH patients, due to
this there was no difference in FXIIa-C1INH levels between
healthy controls and HAE-C1INH patients.
Discussion
The control of the contact system is defective in patients with
HAE-C1INH due to a deficiency in C1INH. Activation of the
contact system triggers the kinin pathway and, as a
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consequence, bradykinin formation is poorly controlled.
Contact activation may also lead to activation of the intrinsic
pathway of coagulation, however, HAE-C1INH patients have
no increased tendency to thrombosis. One mechanism may be
a preferential generation of bradykinin and less activation of the
intrinsic coagulation route, but such mechanisms have not
been explored. Therefore, we investigated if contact activation
in these patients mainly leads to prekallikrein activation and
less to FXI activation.
We determined the activation of the contact system in HAE-
C1INH plasma samples by measuring the levels of C1INH
complexed with FXIIa, kallikrein and FXIa. In accordance with
previous findings from Cugno et al. [23], we did not observe a
difference in the basal levels of the inhibitory complexes in
healthy controls compared to samples of patients with HAE-
C1INH during remission. In a study in five Norwegian patients
with HAE-C1INH, it was found that the levels of FXIa-C1INH
and kallikrein-C1INH were comparable during remission and
during an attack of angioedema [24]. Our results agree with
these findings and furthermore we observed that FXIIa-C1INH
was not increased during an attack of angioedema in these
patients. Since these measurements were performed in plasma
with low levels of C1INH, possibly limiting complex formation,
we also added C1INH to the samples before measurement of
the enzyme-inhibitory complexes. We have shown that
exogenous C1INH is able to form complexes, however, the
addition of C1INH had no effect on the levels of inhibitory
complexes in the basal samples. This indicates that no
uninhibited activated contact factors were present in the
samples. Other pathways of bradykinin formation exist,
however, contact system activation is the main mediator of
attacks of angioedema according to literature [25]. Possibly,
FXIIa was formed but we were unable to measure it because
C1INH cannot (efficiently) inhibit FXIIa, when it is bound to
endothelial cells [26]. Furthermore, enzyme-C1INH complexes
are rapidly cleared from the circulation possibly obscuring
differences in complex concentrations [27–29]. Kallikrein-α2-
macroglobulin complexes, which are cleared at a slower rate
than kallikrein-C1INH, were found to be increased in a patient
with HAE-C1INH during three different acute attacks of
angioedema by Kaufman et al [9].
Next, we activated FXII in the plasma samples with two FXII
triggers: ellagic acid and dextran sulphate. Activation of FXII
with DXS will only activate prekallikrein whereas activation of
FXII with ellagic acid leads to activation of both prekallikrein
and FXI. The rationale to use DXS was that an in vivo activator
with the same properties might mimic the hereditary
angioedema phenotype in which bradykinin formation appears
to prevail over prothrombotic effects (at least without apparent
increased risk of thrombosis). The levels of the inhibitory
complexes after activation were highest in the control group for
both triggers, as expected, but also increased substantially
compared to baseline in the HAE-C1INH patients. This
indicates that even during an acute attack not all plasma
Figure 1.  Enzyme-inhibitory complexes in normal pool plasma after activation with ellagic acid or dextran sulphate.  The
levels of inhibitory complexes were measured by ELISA after activation of normal pool plasma with either ellagic acid or dextran
sulphate (DXS; Mr 500 000). Normal pool plasma was incubated for 25 minutes with either ellagic acid (0.25 mg/ml) or DXS (0.25
mg/ml) at 37oC in Hepes-buffer (25 mM Hepes, 150 mM NaCl, pH = 7.5). The reaction was stopped with stop buffer containing STI
and polybrene. The volume of plasma was 50% of total volume during the activation with ellagic acid or DXS, and diluted further in
the assay. A.U. = Arbitrary units.
doi: 10.1371/journal.pone.0074043.g001
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C1INH is consumed in HAE-C1INH, but this is not sufficiently
capable to control local bradykinin formation. Activation of the
plasma with ellagic acid led to substantial lower levels of
enzyme-C1INH complexes in the plasma of patients with HAE-
C1INH compared to healthy controls, and these levels
remained lower after addition of C1INH (even though the levels
of FXIIa-C1INH and FXIa-C1INH increased in patients after
addition of C1INH). On the other hand, the levels of FXIa-AT
were increased in HAE-C1INH patients compared to healthy
controls. Activation of the plasma with DXS, led to larger
differences in the levels of kallikrein-C1INH between patients
and controls compared to activation of the plasma with ellagic
acid. However, the difference in FXIIa-C1INH levels between
patients and controls was smaller after activation with DXS
compared to activation with ellagic acid, and was not
statistically significant after addition of C1INH. Activation of the
plasma with DXS, led to low levels of FXIa-inhibitor complexes.
Possibly, two different types of FXIIa are formed with the
different activators. α-FXIIa is able to activate both prekallikrein
and FXI (as seen with activation with ellagic acid), whereas β-
FXIIa only activates prekallikrein (as seen with activation with
DXS). The lower levels of FXIIa, FXIa and kallikrein in complex
with C1INH after activation of the plasma from HAE-C1INH
patients, suggest a reduction in the levels of the zymogens of
the contact system. Joseph et al showed that in plasma taken
from HAE-C1INH patients during remission, FXII
spontaneously activates [30]. FXIIa in turn activates
prekallikrein and FXI, leading to consumption of these proteins.
Since both kallikrein-C1INH and FXIa-C1INH were reduced in
plasma from patients compared to plasma from controls,
activation of FXII during attacks of angioedema in these
patients did not predominantly lead to kallikrein formation. This
is in contrast to patients with amyloidosis, where activation of
FXII leads to the formation of kallikrein-C1INH, without
activation of the coagulation system [17]. However, other
inhibitors, such as α2-macroglobulin for kallikrein and α1-
antitrypsin for FXIa are also present in the plasma. The
inhibition of kallikrein by α2M is slower than inhibition by C1INH,
which could explain why the action of this inhibitor is not
sufficient in HAE-C1INH patients to prevent attacks [9].
However, we activated the plasma during 15 min with ellagic
acid or DXS, allowing kallikrein-α2M complexes to form. Only
Figure 2.  Enzyme-inhibitory complexes after activation with ellagic acid in samples from patients and healthy
controls.  Levels of enzyme-inhibitory complexes were measured by ELISA in samples from patients with HAE-C1INH and healthy
controls after activation with ellagic acid, without (black) and with (grey) addition of C1 esterase inhibitor (C1INH) after activation.
Plasma was activated with ellagic acid (0.25 mg/ml) for 15 minutes, than C1INH or Hepes-buffer (25 mM Hepes, 150 mM NaCl, pH
= 7.5) was added and after 10 minutes stop buffer containing STI and polybrene was added. The volume of plasma was 50% of
total volume during the activation with ellagic acid, and diluted further in the assay. Significant differences are indicated in Table 3.
The line represents the median value; A.U. = Arbitrary units.
doi: 10.1371/journal.pone.0074043.g002
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after these 15 min, C1INH was added to the sample.
Therefore, we probably did not see a difference in kallikrein-
C1INH levels before and after addition of C1INH. The fact that
activation of FXI in these patients does not lead to an increase
in thrombosis, may be due to the action of α1-antitrypsin (first
described by Heck et al [31]) and other inhibitors of the
coagulation enzymes downstream in the cascade. C1INH
inhibits the two key enzymes of the kinin system efficiently:
approximately 90% of FXIIa and 50% of kallikrein are inhibited
by C1INH in vitro, while on the coagulation side it provides
approximately 50% inhibition of FXIa [6–9],, but several other
proteins control the cascade. The levels of FXIa-AT after
activation were higher in patients than in healthy controls,
highlighting the action of this inhibitor. Thus, even if we could
not demonstrate a preferential activation of the kinin system,
our data are consistent with the fact that the coagulation
pathway is adequately controlled in patients with HAE-C1INH.
Furthermore, increased fibrinolysis could protect HAE-C1INH
patients during an acute attack against thrombosis. Increased
levels of plasmin α2-antiplasmin (PAP) complexes have
Table 3. Enzyme-inhibitory complexes in HAE-C1INH
patients and healthy controls after activation with ellagic
acid.
 
FXIIa-C1INH
(A.U.)
Kallikrein-
C1INH (A.U.)
FXIa-C1INH
(A.U.) FXIa-AT (A.U.)
 median [IQR] median [IQR] median [IQR] median [IQR]
No addition of C1-esterase inhibitor
Healthy
controls (n =
10)
137.2
[122.6-162.7]
80.0
[74.1-93.1]
84.1
[73.1-97.3]
91.3
[80.3-102.2]
HAE-C1INH
remission (n
= 17)
45.9
[22.8-59.0]*
38.7
[24.6-48.9]*
14.3
[9.9-29.8]*
134.5
[118.4-163.5]*
HAE-C1INH
attack (n =
10)
25.5
[13.3-43.6]*
24.1
[11.1-31.3]*
9.2
1.30-11.0]*
121.6
[89.1-135.6]
Addition of C1-esterase inhibitor
Healthy
controls (n =
10)
114.7
[104.6-132.4]
69.7
[60.3-76.3]
109.2
[97.9-123.5] 88.6 [80.0-95.0]
HAE-C1INH
remission (n
= 16)
77.10
[67.6-86.6]* #
32.3
[25.7-42.9]*
63.8
[44.4-98.1]* #
126.6
[110.3-160.6]*
HAE-C1INH
attack (n = 7)
65.7
[40.7-89.0]* #
17.9
[0.6-36.5]*
32.2
[17.9-50.5]* #
107.8
[100.0-115.1]
C1INH: C1 esterase inhibitor; HAE: hereditary angioedema, IQR: interquartile
range; A.U: arbitrary units
* Significant increase or decrease in level of inhibitory complexes compared to
healthy controls (p < 0.05)
# Significant increase in inhibitory complexes compared to no addition of C1
esterase inhibitor (p < 0.05)
consistently been observed in patients during an acute attack
of angioedema [24,32,33].
FXIIa independent pathways of formation of bradykinin from
HK have been demonstrated. Prolylcarboxypeptidase (PRCP)
[34] and Heat Shock Protein-90 (HSP90) [35] can directly
activate prekallikrein, in complex with HK, bound to endothelial
cells, independent from FXII-activation and prekallikrein itself
has been shown to acquire enzymatic activity when bound to
HK sufficient to cleave HK [36]. Moreover, recent studies have
shown that mannose-binding lectin-associated serine protease
-1 (MASP-1) and to a lesser extent MASP-2, both generated
after activation of the complement system, are able to digest
HK even in the absence of kallikrein. Important to realize for
HAE-C1INH patients is that both the activity of MASP-1 and
MASP-2 are controlled by C1INH [37] and MASP-1 and
MASP-2 levels are elevated during episodes of stress and
infection, known initiators of angioedema episodes.
In conclusion, there was no difference in the basal levels of
the enzyme-inhibitory complexes between remission and attack
samples, indicating that change in contact activation
investigated as C1INH protease complexes was not associated
with the attack. We observed lower levels of the inhibitory
complexes after complete in vitro activation of FXII in the
plasma of HAE-C1INH patients compared to controls. These
reduced levels point to lower levels of FXI, FXII and
Table 4. Enzyme-inhibitory complexes in HAE-C1INH
patients and healthy controls after activation with dextran
sulphate (Mr 500 000).
 
FXIIa-C1INH
(A.U.)
Kallikrein-
C1INH (A.U.)
FXIa-C1INH
(A.U.)
FXIa-AT
(A.U.)
 median [IQR] median [IQR] median [IQR] median [IQR]
No addition of C1-esterase inhibitor
Healthy
controls (n =
10)
54.1
[43.7-81.4]
107
[88.7-125.6]
2.00
[1.62-2.30] 0.65 [0.5-0.96]
HAE-C1INH
remission (n =
16)
21.1
[4.91-32.4]*
37.3
[23.1-59.8]*
2.86
[1.60-5.19]
3.19
[1.64-5.92]*
HAE-C1INH
attack (n = 10)
8.15
[0.5-13.9]*
31.9
[0.5-41.2]*
2.83
[1.06-3.69]
1.90
[1.66-2.01]*
Addition of C1-esterase inhibitor
Healthy
controls (n =
10)
53.0
[36.6-76.1]
88.0
[72.7-101.1]
0.85
[0.69-1.05]
0.73
[0.54-0.99]
HAE-C1INH
remission (n =
15)
44.7
[39.5-52.8] #
34.4
[24.8-45.1]*
2.78
[1.95-6.50]*
1.66
[0.72-2.53]*
HAE-C1INH
attack (n = 6)
47.0
[26.3-56.7] #
30.8
[17.3-37.8]*
10.4
[6.61-14.6]* #
1.31
[1.09-1.60]
C1INH: C1 esterase inhibitor; HAE: hereditary angioedema, IQR: interquartile
range; A.U: arbitrary units
* Significant increase or decrease in level of inhibitory complexes compared to
healthy controls (p < 0.05)
# Significant increase in inhibitory complexes compared to no addition of C1
esterase inhibitor (p < 0.05)
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prekallikrein in these plasmas, probably caused by in vivo
activation and consumption of these proteins. Since our
measurements do not demonstrate preferential activation of the
contact over the coagulation system in HAE-C1INH, the
apparent absence of thrombotic complications during
angioedema attacks is probably due to other regulatory
mechanisms controlling the coagulation cascade (inhibitors of
active coagulation factors) or increased fibrinolysis which
compensates for the increase in coagulation. Consumption of
C1INH in HAE-C1INH patients leads to an unstable
equilibrium. Since C1INH controls several systems that
influence bradykinin formation, any factor that contributes to an
increase in bradykinin formation, such as activation of the
contact system or MASP-1 or MASP-2, could cause an attack
of angioedema.
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